Detalhe da pesquisa
1.
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 41(3): 380-390, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040046
2.
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Invest New Drugs
; 40(3): 586-595, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35113285
3.
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Invest New Drugs
; 38(1): 120-130, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30887250
4.
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Invest New Drugs
; 38(5): 1483-1494, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32189093
5.
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Cancer
; 124(10): 2174-2183, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29533458
6.
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Invest New Drugs
; 36(4): 629-637, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29196957
7.
Improving combination cancer therapy: the CombiPlex® development platform.
Future Oncol
; 14(13): 1317-1332, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29363994
8.
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Br J Cancer
; 116(5): 575-583, 2017 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28152546
9.
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
Invest New Drugs
; 34(2): 216-24, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26924128
10.
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 16(5): 531-40, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25864104
11.
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.
Invest New Drugs
; 32(4): 653-60, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24604265
12.
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Clin Cancer Res
; 30(10): 2057-2067, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407317
13.
Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38295150
14.
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol
; : JCO2301909, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652877
15.
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Drug Metab Dispos
; 41(12): 2104-13, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24041744
16.
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-ß-trap bifunctional antibody, in patients with advanced solid tumors.
J Immunother Cancer
; 11(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746510
17.
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
J Clin Oncol
; 41(29): 4678-4687, 2023 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37327461
18.
Antibody drug conjugates: The dos and don'ts in clinical development.
Pharmacol Ther
; 240: 108235, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35738430
19.
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
Chin J Cancer
; 30(12): 815-20, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22059910
20.
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Clin Cancer Res
; 27(16): 4511-4520, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34083232